Sign Up
OverviewAPI
DeepMirror, a University of Cambridge spin-out, launches Early Access Programme for its intuitive molecular drug design software, aiming to accelerate therapeutic drug discovery. The software leverages AI to enhance molecular design and predict properties such as drug binding, bio-activity, and toxicity.

Ask a question